Abstract 2039P
Background
Reliable and validated primary endpoints, such as overall survival (OS), are commonly used in oncologic confirmatory randomized controlled trials (RCTs). However, recent studies suggest that these endpoints may not sufficiently measure the true benefits of therapies in older patients with cancer. We conducted a scoping review of the literature to identify primary endpoints used in geriatric oncology RCTs.
Methods
We searched the literature on confirmatory RCTs specific to older patients with cancer using PubMed (National Center for Biotechnology Information) and CINAHL (EBSCO). Studies fulfilling the selection criteria were reviewed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews, and definitions of primary endpoints were extracted.
Results
A total of 68 RCTs met the inclusion criteria. Data on geriatric assessment and quality of life (QOL) were extracted in 66 (97.1%) and 25 (36.8%) RCTs, respectively. Fifty-two RCTs (76.5%) used traditional outcomes, such as OS, DFS, relapse-free survival, progression-free survival, and response rate, as primary endpoints; however, one RCT used OS adjusted for QOL as a primary endpoint and one RCT used OS and health-related QOL as a combination primary endpoint. Three of the four RCTs using time-to-event endpoint as the primary endpoint included toxic effect as an event in addition to disease progression and death due to any cause. Toxic effect was a primary outcome measure in six RCTs (8.8%) which utilized the National Cancer Institute Common Terminology Criteria for Adverse Events. Health-related QOL, including the EORTC QOL Questionnaire core version 30 items, was a primary endpoint in three RCTs (4.4%). Barthel index for activities of daily living and the confusion assessment method for delirium were used in two RCTs (2.9%).
Conclusions
Although most geriatric oncology RCTs used traditional primary endpoints, some RCTs utilized innovative primary endpoints to more appropriately measure treatment benefit for older patients with cancer. This scoping review should be helpful for methodological discussions among investigators and efficient use of these endpoints.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06